Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 251, 235-44; discussion 245-9, 281-97

Why Have Drug Treatments Been So Disappointing?

Affiliations
  • PMID: 14521196

Why Have Drug Treatments Been So Disappointing?

Jan K Buitelaar. Novartis Found Symp.

Abstract

The title of this contribution involves two consecutive questions: have the effects of medication in autism indeed been disappointing? And if so, why? The answer to the first question depends on whether one focuses on the core social and communicative deficits of autism, or on various complicating behaviour problems. Attempts over the past decades to develop drugs that specifically improve social and communicative functioning have failed. Among the most ambitious attempts were medical interventions in the endogenous opioid system that were motivated from animal models on the involvement of this system in various aspects of social behaviour. By contrast, medications such as the newer antipsychotics, psychostimulants, presynaptic noradrenergic blocking agents (clonidine and guanfacine) and selective serotonin reuptake inhibitors were shown to reduce impairing complicating symptoms of affective instability, irritability, hyperactivity and inattentiveness, aggression, self-injury and stereotypies. The explanation for the medication-refractory status of social and communicative deficits should be sought in at least two related factors: (1) the as yet unidentified neurochemical basis of autism, and (2) the obvious lack of involvement of the main neurotransmitter systems (dopamine, noradrenaline and serotonin) in the pathophysiology of social and communicative behaviour.

Similar articles

See all similar articles

Cited by 6 PubMed Central articles

  • Exploring the Validity of Valproic Acid Animal Model of Autism
    DF Mabunga et al. Exp Neurobiol 24 (4), 285-300. PMID 26713077. - Review
    The valproic acid (VPA) animal model of autism spectrum disorder (ASD) is one of the most widely used animal model in the field. Like any other disease models, it can't m …
  • Using Genetic Findings in Autism for the Development of New Pharmaceutical Compounds
    JA Vorstman et al. Psychopharmacology (Berl) 231 (6), 1063-78. PMID 24292384. - Review
    An increasing number of genetic variants associated with autism have been identified. This will generate new ideas about the biological mechanisms involved in autism, whi …
  • Autism
    J Parr. BMJ Clin Evid 2010. PMID 21729335. - Review
    In this systematic review we present information relating to the effectiveness and safety of the following interventions: applied behavioural analysis; auditory integrati …
  • Progress in Understanding Autism: 2007-2010
    ML Rutter. J Autism Dev Disord 41 (4), 395-404. PMID 21318644. - Review
    Scientific progress is discussed in relation to clinical issues; genetic issues; environmental issues; and the state of play on psychological treatments. It is concluded …
  • Tetrahydrobiopterin as a Novel Therapeutic Intervention for Autism
    RE Frye et al. Neurotherapeutics 7 (3), 241-9. PMID 20643376. - Review
    Tetrahydrobiopterin (BH(4)) is an essential cofactor for several critical metabolic pathways that have been reported to be abnormal in autism spectrum disorder (ASD). In …
See all "Cited by" articles

LinkOut - more resources

Feedback